Rgenix to Present Early Clinical Data on RGX-104 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
New York, NY – October 26, 2017 - Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Dr. Monica Mita of Cedars-Sinai Medical Center and Principal Investigator of the RGX-104-001 study, will
Rgenix Announces $33 Million Series B Financing to Develop First-in-Class Cancer Therapeutics
Novo A/S and Sofinnova Partners are leading this latest financing round NEW YORK, New York ― June 15, 2016 ― Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by